These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2475344)

  • 1. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
    Oosterom R; Bogdanowicz J; Schröder FH
    Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM; Bogdanowicz JF; Oosterom R; Schröder FH
    Ned Tijdschr Geneeskd; 1990 Aug; 134(33):1596-600. PubMed ID: 1697651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Discrepancy between the serum levels of gamma seminoprotein and prostate-specific antigen in patients with prostatic neoplasms. Both true or either untrue].
    Fujino A; Mukai N; Kawakami T; Yokoyama E; Mashimo S; Endo T; Ishibashi A; Koshiba K; Aoki Y; Itoh H
    Nihon Hinyokika Gakkai Zasshi; 1991 Apr; 82(4):541-50. PubMed ID: 1711133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase.
    Ferro MA; Barnes I; Roberts JB; Smith PJ
    Br J Urol; 1987 Jul; 60(1):69-73. PubMed ID: 2441790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.
    van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ
    Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medically significant concentrations of prostate-specific antigen in serum assessed.
    Bernstein LH; Rudolph RA; Pinto MM; Viner N; Zuckerman H
    Clin Chem; 1990 Mar; 36(3):515-8. PubMed ID: 1690092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen as a marker of adenocarcinoma of prostate.
    Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
    Urol Res; 1989; 17(4):245-9. PubMed ID: 2475959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the clinical usefulness of prostate specific antigen and prostatic acid phosphatase in prostatic disease.
    Buamah PK; Johnson P; Skillen AW
    Br J Urol; 1988 Dec; 62(6):581-3. PubMed ID: 2464396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer.
    Waehre H; Wanderaas EH; Paus E; Fosså SD
    Eur Urol; 1992; 22(1):33-8. PubMed ID: 1385143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is prostate-specific antigen the most useful marker for screening in prostate cancer?
    Delaere KP; Van Dieijen-Visser MP; Gijzen AH; Brombacher PJ
    Am J Clin Oncol; 1988; 11 Suppl 2():S65-7. PubMed ID: 2468276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
    Guillet J; Role C; Duc AT; François H
    Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.
    Rock RC; Chan DW; Bruzek D; Waldron C; Oesterling J; Walsh P
    Clin Chem; 1987 Dec; 33(12):2257-61. PubMed ID: 2446807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
    Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.
    Pretlow TG; Pretlow TP; Yang B; Kaetzel CS; Delmoro CM; Kamis SM; Bodner DR; Kursh E; Resnick MI; Bradley EL
    Int J Cancer; 1991 Nov; 49(5):645-9. PubMed ID: 1718912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
    Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC
    JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of PSA and PAP in patients with or without prostatic cancer.
    Caty A; Gosselin P; Cazin JL; Dehaut JM; Adenis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S63-4. PubMed ID: 2468275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.